54 related articles for article (PubMed ID: 31876205)
1. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
Mounié M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
[No Abstract] [Full Text] [Related]
2. Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain.
Bosch X; Sanclemente-Ansó C; Escoda O; Monclús E; Franco-Vanegas J; Moreno P; Guerra-García M; Guasch N; López-Soto A
BMC Cancer; 2018 Mar; 18(1):276. PubMed ID: 29530002
[TBL] [Abstract][Full Text] [Related]
3. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.
Wang HI; Smith A; Aas E; Roman E; Crouch S; Burton C; Patmore R
Eur J Health Econ; 2017 Mar; 18(2):255-267. PubMed ID: 26969332
[TBL] [Abstract][Full Text] [Related]
4. Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018-2040.
Ortega-Ortega M; Hanly P; Pearce A; Soerjomataram I; Sharp L
Appl Health Econ Health Policy; 2023 Nov; 21(6):877-889. PubMed ID: 37552416
[TBL] [Abstract][Full Text] [Related]
5. Cost of Treating Pediatric Cancer at the Butaro Cancer Center of Excellence in Rwanda.
Neal C; Rusangwa C; Borg R; Mugunga JC; Kennell-Heiling S; Shyirambere C; Pritchett N; Muhayimana C; Ntakirutimana E; Tapela N; Park PH; Shulman LN; Mpunga T
J Glob Oncol; 2018 Nov; 4():1-7. PubMed ID: 30433841
[TBL] [Abstract][Full Text] [Related]
6. Microcosting Analysis of Advanced Ovarian Cancer: Real-World Evidence From the Perspective of a Reference Public Brazilian Hospital.
Martins C; Padilha R; Okumura L; Melo A; Costa R
Value Health Reg Issues; 2024 May; 43():100999. PubMed ID: 38714096
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum to "Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database".
Eur J Neurol; 2024 Jun; 31(6):e16218. PubMed ID: 38323689
[No Abstract] [Full Text] [Related]
8. Mind the Gap Between Clinical Trials and Real World Data: Learning From Patients Revascularised for Peripheral Artery Disease in France.
Lareyre F; Raffort J
Eur J Vasc Endovasc Surg; 2024 Feb; ():. PubMed ID: 38428667
[No Abstract] [Full Text] [Related]
9. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima
Lee K; Ha JY; Jung AR; Lee YS; Lee SW; Ryu JS; Chae EJ; Kim KW; Huh J; Park CS; Yoon DH; Suh C
Leuk Lymphoma; 2020 Jul; 61(7):1575-1583. PubMed ID: 32290739
[TBL] [Abstract][Full Text] [Related]
10. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model.
Mahmoud R; van Lieshout C; Frederix GWJ; Jharap B; Oldenburg B
J Crohns Colitis; 2021 May; 15(5):709-718. PubMed ID: 33125060
[TBL] [Abstract][Full Text] [Related]
11. Budget Impact Analysis of Switching to Rituximab's Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa.
Almaaytah A
Clinicoecon Outcomes Res; 2020; 12():527-534. PubMed ID: 32982342
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in oncology: Effects on economy and therapeutic innovations.
Hübel K; Kron F; Lux MP
Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
[TBL] [Abstract][Full Text] [Related]
13. How do biosimilars sustain value, affordability, and access to oncology care?
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
[No Abstract] [Full Text] [Related]
14. Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018).
Agirrezabal I; Sánchez-Iriso E; Mandar K; Cabasés JM
Diabetes Care; 2020 Aug; 43(8):1767-1773. PubMed ID: 32527798
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
Aungsumart S; Apiwattanakul M
PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
[TBL] [Abstract][Full Text] [Related]
17. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies.
Obianom ON; Okusanya OO; Earp J; Thway TM
Clin Pharmacol Ther; 2020 Jul; 108(1):107-115. PubMed ID: 31957006
[TBL] [Abstract][Full Text] [Related]
18. Real world data to identify target population for new CAR-T therapies.
Belleudi V; Trotta F; Fortinguerra F; Poggi FR; Olimpieri O; Santelli E; Cozzi I; Michelozzi P; Addis A
Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):78-85. PubMed ID: 33108004
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group.
Kagami Y; Ariyoshi Y; Horiuchi A; Kanamaru A; Kano Y; Naoe T; Oguro M; Ohno R; Sampi K; Shirakawa S; Masaoka T; Furue H
Int J Hematol; 1996 Oct; 64(3-4):221-9. PubMed ID: 8923784
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo: Epidemiology and Economic Impact.
Naldi L; Pagani A; Alduini C
Dermatol Pract Concept; 2023 Dec; 13(4S2):. PubMed ID: 38241395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
